Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adaptive response

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    214 result(s) found for: Adaptive response. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-003405-98 Sponsor Protocol Number: dexFEMv2 Start Date*: 2012-12-03
    Sponsor Name:ACCORD University of Edinburgh [...]
    1. ACCORD University of Edinburgh
    2. ACCORD, NHS Lothian
    Full Title: Developmental Clinical Studies - Reversing endometrial glucocorticoid deficiency in heavy menstrual bleeding
    Medical condition: Endometrial glucocorticoid deficiency in Heavy Menstrual Bleeding
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10027313 Menorrhagia PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003173-22 Sponsor Protocol Number: BP30153 Start Date*: 2020-11-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II Multi-Center, Randomized, Double-Blind, 24-Week, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Children and Adolescents Age...
    Medical condition: Autism Spectrum Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000116-42 Sponsor Protocol Number: BioVacSafe-QIV Start Date*: 2017-03-02
    Sponsor Name:Ghent University Hospital
    Full Title: A clinical study of biomarkers of innate and adaptive immune activation associated with symptoms and immune responses after administration of a single dose of a quadrivalent inactivated split virus...
    Medical condition: Healthy Volunteers - a quadrivalent inactivated split virus influenza vaccine
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003543-35 Sponsor Protocol Number: BioVacSafe–FluadTM Start Date*: 2014-09-23
    Sponsor Name:Ghent University Hospital
    Full Title: A clinical study to generate a set of data characterising clinical events, physiological responses, and innate and adaptive immune responses following a single intramuscular immunisation with Fluad...
    Medical condition: vaccin against influenza
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001411-39 Sponsor Protocol Number: ABT-002 Start Date*: 2018-09-04
    Sponsor Name:Abeona Therapeutics Inc
    Full Title: Phase I/II gene transfer clinical trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB
    Medical condition: MPS IIIB is a devastating lysosomal storage disease, caused by a N-α-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progre...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-003124-12 Sponsor Protocol Number: B-40320109424 Start Date*: 2012-10-30
    Sponsor Name:Cliniques Universitaires Saint Luc
    Full Title: A prospective phase II study on dose escalation using PET based adaptive IMRT stage II-III non small lung cancer
    Medical condition: Stage II-III Non small lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002250-24 Sponsor Protocol Number: GCAR-7213 Start Date*: 2021-12-07
    Sponsor Name:Global Coalition for Adaptive Research
    Full Title: GCAR-7213: GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Di...
    Medical condition: Oncology - Glioblastoma (GBM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FR (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000907-27 Sponsor Protocol Number: D2782C00010 Start Date*: 2008-10-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced Ur...
    Medical condition: Stage IV urothelial Cancer Cáncer de urotelio estadío 4
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000359-26 Sponsor Protocol Number: ESTEVE-SANF-201 Start Date*: 2016-04-29
    Sponsor Name:Laboratorios del Dr. Esteve, S.A.
    Full Title: Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients wit...
    Medical condition: Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome) is an inherited lysosomal storage disease caused by a specific lysosomal enzyme deficiency that leads to intracellular accumulation of the ...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000504-42 Sponsor Protocol Number: ABT-003 Start Date*: 2019-05-21
    Sponsor Name:Abeona Therapeutics Inc
    Full Title: A Phase I/II Open Label, Single-dose, Gene Transfer Study of scAAV9.U1a.hSGSH (ABO-102) in Patients with Middle and Advanced Phases of MPS IIIA Disease
    Medical condition: MPS IIIA is a devastating lysosomal storage disease, caused by a Nsulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progress...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056890 Mucopolysaccharidosis III PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003759-13 Sponsor Protocol Number: GI1931 Start Date*: 2019-12-20
    Sponsor Name:Department of Oncology, Herlev & Gentofte
    Full Title: Phase 1/2 study in borderline resectable, locally advanced or metastatic pancreatic cancer to assess safety and potential efficacy of dual checkpoint inhibition in combination with gemcitabine and ...
    Medical condition: Locally advanced pancreatic cancer, non-resectable or borderline resectable, or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004349-42 Sponsor Protocol Number: NP27936 Start Date*: 2012-07-16
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, double-blind, 12- week, parallel group, placebo-controlled study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome.
    Medical condition: Fragile X Syndrome (FXS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10025463 Major depressive disorder, single episode LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) ES (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2012-001344-22 Sponsor Protocol Number: 116640 Start Date*: 2013-02-19
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomised, single-blind study to develop read-outs aimed at detecting and characterising the early and adaptive immune responses and to evaluate the kinetics of the early response and ...
    Medical condition: Healthy volunteers (Hepatitis B surface antigen (HBsAg) vaccine administered in hepatitis B virus (HBV) naive adult subjects aged between 18 and 45 years old, inclusive, in good general health.)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006134-17 Sponsor Protocol Number: IPM3002 Start Date*: 2012-07-30
    Sponsor Name:ZIOPHARM Oncology, Inc.
    Full Title: A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etopo...
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) PL (Completed) IT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-000381-39 Sponsor Protocol Number: KCL/DS/MEM/1 Start Date*: 2005-08-24
    Sponsor Name:King's College London
    Full Title: Efficacy and Safety of Memantine Hydrochloride, a low affinity antagonist to N-Methyl-D-Aspartate (NMDA) type receptors, in the prevention of cognitive decline and disease progression in older peop...
    Medical condition: Cognitive decline and dementia in Down's syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006024-35 Sponsor Protocol Number: cysteamine gel formulation/07/cysta Start Date*: 2008-02-04
    Sponsor Name:Orphan Europe SARL
    Full Title: Adaptive dose regimen of Cystadrops for cOrneal Crystal deposiTs and ocular manifestations in nephropathic cystinosis : an open label, dose-response pilot study
    Medical condition: Nephropathic cystinotic patients with cystine crystals corneal deposits
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-002120-37 Sponsor Protocol Number: RESP301-002 Start Date*: 2020-06-16
    Sponsor Name:Thirty Respiratory Limited
    Full Title: An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with C...
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10061986 SARS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-002879-14 Sponsor Protocol Number: BioVacSafe-Boostrix® Start Date*: 2015-07-30
    Sponsor Name:Ghent University Hospital
    Full Title: BioVacSafe-Boostrix®: een klinische studie om een reeks gegevens te regenereren die kenmerkend zijn voor klinische gebeurtenissen, fysiologische reacties en aangeboren en adaptieve immuunreacties v...
    Medical condition: vaccin against diphtheria, tetanus and pertussis.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004526-29 Sponsor Protocol Number: uni-koeln-4602 Start Date*: 2021-10-19
    Sponsor Name:University of Cologne
    Full Title: A MULTINATIONAL, PHASE 2, RANDOMISED, ADAPTIVE PROTOCOL TO EVALUATE IMMUNOGENICITY AND REACTOGENICITY OF DIFFERENT COVID-19 VACCINES ADMINISTRATION IN OLDER ADULTS (≥75) ALREADY VACCINATED AGAINST ...
    Medical condition: Prevention of COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    24.0 100000004865 10085559 Revaccination with different COVID-19 vaccine LLT
    23.0 100000004865 10084462 SARS-CoV-2 vaccination LLT
    23.0 100000004865 10084463 SARS-CoV-2 immunisation LLT
    23.0 100000004865 10084466 SARS-CoV-2 immunization LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) IE (Completed) ES (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001978-37 Sponsor Protocol Number: CombiVacS Start Date*: 2021-04-19
    Sponsor Name:Instituto de Salud Carlos III. ISCIII
    Full Title: A Phase 2, Comparative, Randomised, Adaptive Trial to Evaluate the safety and immunogenicity of one dose of COMIRNATY in subjects that had received one dose of VAXZEVRIA.
    Medical condition: Covid-19 Vaccination
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 21:49:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA